WO1997015549A1 - COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION - Google Patents

COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION Download PDF

Info

Publication number
WO1997015549A1
WO1997015549A1 PCT/JP1996/003097 JP9603097W WO9715549A1 WO 1997015549 A1 WO1997015549 A1 WO 1997015549A1 JP 9603097 W JP9603097 W JP 9603097W WO 9715549 A1 WO9715549 A1 WO 9715549A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
lower alkoxy
substituted
agonist
intermediates
Prior art date
Application number
PCT/JP1996/003097
Other languages
English (en)
French (fr)
Inventor
Susumu Tsuchiya
Nobuyuki Yasuda
Toshifumi Matsumoto
Kozo Hiratsuka
Hiroyuki Iizuka
Atsusi Hukuzaki
Kouichi Matsunaga
Original Assignee
Tokyo Tanabe Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Tanabe Company Limited filed Critical Tokyo Tanabe Company Limited
Priority to KR10-1998-0703029A priority Critical patent/KR100483635B1/ko
Priority to AU73358/96A priority patent/AU715216B2/en
Priority to EP96935424A priority patent/EP0940387B1/en
Priority to AT96935424T priority patent/ATE239694T1/de
Priority to US09/065,077 priority patent/US6069176A/en
Priority to JP51647697A priority patent/JP3926390B2/ja
Priority to CA002235840A priority patent/CA2235840C/en
Priority to DE69628051T priority patent/DE69628051T2/de
Publication of WO1997015549A1 publication Critical patent/WO1997015549A1/ja
Priority to NO981858A priority patent/NO981858L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
PCT/JP1996/003097 1995-10-26 1996-10-24 COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION WO1997015549A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR10-1998-0703029A KR100483635B1 (ko) 1995-10-26 1996-10-24 β3작동약으로서유용한페닐에탄올아민화합물,그의제법및그의제조에서의중간체
AU73358/96A AU715216B2 (en) 1995-10-26 1996-10-24 Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
EP96935424A EP0940387B1 (en) 1995-10-26 1996-10-24 Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
AT96935424T ATE239694T1 (de) 1995-10-26 1996-10-24 Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
US09/065,077 US6069176A (en) 1995-10-26 1996-10-24 Phenylethanolamine compounds useful as β 3 agonists, process for producing the same, and intermediates in the production of the same
JP51647697A JP3926390B2 (ja) 1995-10-26 1996-10-24 β3作業薬として有用なフェニルエタノールアミン化合物、その製法およびその製造における中間体
CA002235840A CA2235840C (en) 1995-10-26 1996-10-24 Phenylethanolamine compounds useful as .beta.3 agonist, process for producing the same, and intermediates in the production of the same
DE69628051T DE69628051T2 (de) 1995-10-26 1996-10-24 Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
NO981858A NO981858L (no) 1995-10-26 1998-04-24 Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP27855495 1995-10-26
JP7/278554 1995-10-26
JP24962296 1996-09-20
JP8/249622 1996-09-20

Publications (1)

Publication Number Publication Date
WO1997015549A1 true WO1997015549A1 (fr) 1997-05-01

Family

ID=26539396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/003097 WO1997015549A1 (fr) 1995-10-26 1996-10-24 COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION

Country Status (12)

Country Link
US (1) US6069176A (ja)
EP (1) EP0940387B1 (ja)
JP (1) JP3926390B2 (ja)
KR (1) KR100483635B1 (ja)
AT (1) ATE239694T1 (ja)
AU (1) AU715216B2 (ja)
CZ (1) CZ126598A3 (ja)
DE (1) DE69628051T2 (ja)
ES (1) ES2193266T3 (ja)
HU (1) HUP9802318A3 (ja)
NO (1) NO981858L (ja)
WO (1) WO1997015549A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024754A1 (fr) * 1996-12-04 1998-06-11 Kureha Kagaku Kogyo Kabushiki Kaisha Derives de la cyclopentyleamine, leur procede de preparation et bactericides
EP0982026A2 (en) * 1998-08-18 2000-03-01 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
US6184236B1 (en) 1998-08-18 2001-02-06 Hoffmann-La Roche Inc. Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative
EP0958835A4 (en) * 1996-08-19 2001-04-18 Kissei Pharmaceutical THERAPEUTIC OR PREVENTIVE REMEDY AGAINST INCONTINENCE OR FREQUENT URINARY ELIMINATION
WO2002006232A1 (en) * 2000-07-17 2002-01-24 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1382333A3 (en) * 1998-04-06 2004-02-04 Fujisawa Pharmaceutical Co., Ltd. Use of beta 3 adrenergic receptor agonists in the treatment of dysuria
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
WO2006043577A1 (ja) * 2004-10-20 2006-04-27 Mitsubishi Pharma Corporation フェニルエタノールアミン化合物の製造方法及びその中間体
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
JP2008515962A (ja) * 2004-10-12 2008-05-15 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
JP2013531662A (ja) * 2010-06-30 2013-08-08 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
JP2013531661A (ja) * 2010-06-30 2013-08-08 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
WO2014033343A1 (es) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US8835474B2 (en) 2002-11-07 2014-09-16 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
JP2016047815A (ja) * 2014-08-25 2016-04-07 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
MXPA02009659A (es) * 2000-04-26 2003-03-10 Warner Lambert Co Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda.
EP1296934A1 (en) 2000-06-01 2003-04-02 Warner-Lambert Company Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
CA2407164A1 (en) * 2000-06-06 2001-12-13 Warner-Lambert Company Bicyclic cyclohexylamines and their use as nmda receptor antagonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
GB0217211D0 (en) * 2002-07-24 2002-09-04 Syngenta Participations Ag Organic compounds
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
SI1599468T1 (sl) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
JP2006516572A (ja) * 2003-01-14 2006-07-06 アリーナ ファーマシューティカルズ, インコーポレイテッド 代謝モジュレーターとしての1,2,3−トリ置換アリール誘導体および1,2,3−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MXPA06004625A (es) * 2003-11-03 2006-06-27 Boehringer Ingelheim Int Composicion famaceutica que contiene un agonista de un adrenoceptor beta-3 y un antagonista alfa y/o un inhibidor de la 5-alfa-reductasa.
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20080064758A1 (en) * 2006-08-23 2008-03-13 Medicinova, Inc. Method of treatment or prophylaxis of depression
KR100821567B1 (ko) 2006-11-01 2008-04-15 한국화학연구원 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법
WO2008073623A2 (en) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
JP5420534B2 (ja) * 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
MX2010005631A (es) * 2007-11-23 2010-06-02 Leo Pharma As Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
JP2013535486A (ja) 2010-08-03 2013-09-12 アルセレックス,インコーポレイテッド 過活動膀胱を治療するためのβ−3アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN108349891B (zh) 2015-06-22 2022-04-05 艾尼纳制药公司 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
DK3365321T3 (da) 2015-10-23 2024-01-15 B3Ar Therapeutics Inc Solabegron-zwitterion og anvendelser deraf

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803232A (en) * 1970-09-30 1974-04-09 Ciba Geigy Corp Arylcarboxamidines
JPS4940226B1 (ja) * 1970-05-02 1974-10-31
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
JPS62198639A (ja) * 1986-02-26 1987-09-02 Takasago Corp α−アリ−ルカルボニル誘導体の製造法
US4755505A (en) * 1987-08-18 1988-07-05 American Home Products Corporation 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents
JPH01135739A (ja) * 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc 2−(4−ヒドロキシフェニル)−シクロヘキサノンの製造方法
JPH04169595A (ja) * 1990-11-01 1992-06-17 Daicel Chem Ind Ltd 分離剤
JPH04211636A (ja) * 1990-03-06 1992-08-03 Basf Ag 4−(4−第三ブチルフェニル)シクロヘキシルアミンおよびその4級アンモニウム塩、および該化合物を含有する殺菌剤
JPH0665107A (ja) * 1991-10-28 1994-03-08 Snow Brand Milk Prod Co Ltd 含窒素化合物の水素化還元方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517617B2 (ja) * 1972-08-25 1976-03-09
FR2643076B1 (fr) * 1989-02-14 1991-06-21 Midy Spa Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
DE4210569A1 (de) * 1992-03-31 1993-10-07 Hoechst Ag Verwendung von substituierten µ-Hydroxyethylaminen als fungizide Wirkstoffe

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940226B1 (ja) * 1970-05-02 1974-10-31
US3803232A (en) * 1970-09-30 1974-04-09 Ciba Geigy Corp Arylcarboxamidines
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
JPS62198639A (ja) * 1986-02-26 1987-09-02 Takasago Corp α−アリ−ルカルボニル誘導体の製造法
US4755505A (en) * 1987-08-18 1988-07-05 American Home Products Corporation 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents
JPH01135739A (ja) * 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc 2−(4−ヒドロキシフェニル)−シクロヘキサノンの製造方法
JPH04211636A (ja) * 1990-03-06 1992-08-03 Basf Ag 4−(4−第三ブチルフェニル)シクロヘキシルアミンおよびその4級アンモニウム塩、および該化合物を含有する殺菌剤
JPH04169595A (ja) * 1990-11-01 1992-06-17 Daicel Chem Ind Ltd 分離剤
JPH0665107A (ja) * 1991-10-28 1994-03-08 Snow Brand Milk Prod Co Ltd 含窒素化合物の水素化還元方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 1980, 93:26036. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958835A4 (en) * 1996-08-19 2001-04-18 Kissei Pharmaceutical THERAPEUTIC OR PREVENTIVE REMEDY AGAINST INCONTINENCE OR FREQUENT URINARY ELIMINATION
WO1998024754A1 (fr) * 1996-12-04 1998-06-11 Kureha Kagaku Kogyo Kabushiki Kaisha Derives de la cyclopentyleamine, leur procede de preparation et bactericides
EP1382333A3 (en) * 1998-04-06 2004-02-04 Fujisawa Pharmaceutical Co., Ltd. Use of beta 3 adrenergic receptor agonists in the treatment of dysuria
US6184236B1 (en) 1998-08-18 2001-02-06 Hoffmann-La Roche Inc. Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative
EP0982026A3 (en) * 1998-08-18 2001-06-13 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
EP0982026A2 (en) * 1998-08-18 2000-03-01 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US6933319B2 (en) 1999-03-22 2005-08-23 Pfizer Inc. Resorcinol derivatives
WO2002006232A1 (en) * 2000-07-17 2002-01-24 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US8835474B2 (en) 2002-11-07 2014-09-16 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
JP2008515962A (ja) * 2004-10-12 2008-05-15 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
WO2006043577A1 (ja) * 2004-10-20 2006-04-27 Mitsubishi Pharma Corporation フェニルエタノールアミン化合物の製造方法及びその中間体
JPWO2006043577A1 (ja) * 2004-10-20 2008-05-22 田辺三菱製薬株式会社 フェニルエタノールアミン化合物の製造方法及びその中間体
US7544841B2 (en) 2004-10-20 2009-06-09 Mitsubishi Tanabe Pharma Corporation Production method of phenylethanolamine compound, and its intermediate
JP4889501B2 (ja) * 2004-10-20 2012-03-07 田辺三菱製薬株式会社 フェニルエタノールアミン化合物の製造方法及びその中間体
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
JP2013531661A (ja) * 2010-06-30 2013-08-08 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
JP2013531662A (ja) * 2010-06-30 2013-08-08 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
WO2014033343A1 (es) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP2016047815A (ja) * 2014-08-25 2016-04-07 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法

Also Published As

Publication number Publication date
ES2193266T3 (es) 2003-11-01
AU7335896A (en) 1997-05-15
EP0940387B1 (en) 2003-05-07
NO981858D0 (no) 1998-04-24
KR100483635B1 (ko) 2005-12-21
KR19990067089A (ko) 1999-08-16
NO981858L (no) 1998-06-24
AU715216B2 (en) 2000-01-20
ATE239694T1 (de) 2003-05-15
EP0940387A1 (en) 1999-09-08
EP0940387A4 (en) 2000-07-05
HUP9802318A2 (hu) 1999-08-30
DE69628051T2 (de) 2004-02-26
DE69628051D1 (de) 2003-06-12
CZ126598A3 (cs) 1998-09-16
HUP9802318A3 (en) 2001-04-28
US6069176A (en) 2000-05-30
JP3926390B2 (ja) 2007-06-06

Similar Documents

Publication Publication Date Title
WO1997015549A1 (fr) COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION
UA35564C2 (uk) Поліциклічні аміновмісні сполуки, що є антагоністами рецепторів нейрокінінів, їх фармацевтично прийнятні енантіомери, солі, n-оксиди і продукти кватернізації, спосіб їх отримання, проміжні сполуки і фармацевтична композиція
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
WO2004072025A3 (de) Substituierte n-arylheterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
RS52142B (sr) 8-[3-amino-piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao farmaceutskih kompozicija
WO2005058884A3 (en) Cyclopropane compounds and pharmaceutical use thereof
ATE396999T1 (de) Morphinanderivate substituiert in position 14 und deren quartäre ammoniumsalze, herstellungsverfahren und verwendung
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2004037811A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
SI1501808T1 (sl) Antagonisti tahikininskega receptorja
EP2982668A3 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
ATE332304T1 (de) Cefdinir salze als zwischenprodukte
WO2006076452A8 (en) An exo-selective synthesis of himbacine analogs
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
YU101103A (en) Technical synthesis method for producing tropenol
WO2005087770A3 (de) 5, 6-dihydrocarbyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
CA2235840A1 (en) Phenylethanolamine compounds useful as .beta.3 agonist, process for producing the same, and intermediates in the production of the same
BR9806875A (pt) Processo para a preparação de um composto.
ATE280769T1 (de) Verfahren zur herstellung von vitronectin- rezeptorantagonisten
MX2007000042A (es) Metodo para producir una forma enantiomerica de derivados de acido 2,3-diaminopropionico.
WO2003057668A1 (fr) Derive de cetone cyclique azote, procede permettant de produire ce derive et utilisation de ce derive
AU2003259529A1 (en) Process for preparing haloalkyl pyrimidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2235840

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2235840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003256

Country of ref document: MX

Ref document number: PV1998-1265

Country of ref document: CZ

Ref document number: 09065077

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019980703029

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996935424

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-1265

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980703029

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996935424

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996935424

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-1265

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1019980703029

Country of ref document: KR